Biotech Values

[DewDiligence]

›Vertex, and many of the leading physicians, will also keep their eyes open at this meeting for innovative new treatments that are at earlier stages of development than telaprevir. Two different types of antiviral drugs, polymerase inhibitors and NS5A inhibitors, are being tested along with telaprevir to see if they can help boost the cure rates even higher, Graves says. “Can we get rid of interferon and ribavirin while we improve cure rates? …That’s the ultimate goal, and the next major step forward.”‹

http://www.xconomy.com/boston/2008/10/29/vertex-gears-up-for-big-liver-disease-conference/